SUMOylation of Tissue Transglutaminase as Link between Oxidative Stress and Inflammation1

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CF is characterized by chronic bacterial lung infections and inflammation, and we have previously reported that tissue transglutaminase (TG2), a multifunctional enzyme critical to several diseases, is constitutively up-regulated in CF airways and drives chronic inflammation. Here, we demonstrate that the generation of an oxidative stress induced by CFTR-defective function leads to protein inhibitor of activated STAT (PIAS)y-mediated TG2 SUMOylation and inhibits TG2 ubiquitination and proteasome degradation, leading to sustained TG2 activation. This prevents peroxisome proliferator-activated receptor (PPAR)γ and IkBα SUMOylation, leading to NF-κB activation and to an uncontrolled inflammatory response. Cellular homeostasis can be restored by small ubiquitin-like modifier (SUMO)-1 or PIASy gene silencing, which induce TG2 ubiquitination and proteasome degradation, restore PPARγ SUMOylation, and prevent IkBα cross-linking and degradation, thus switching off inflammation. Manganese superoxide dismutase overexpression as well as the treatment with the synthetic superoxide dismutase mimetic EUK-134 control PIASy-TG2 interaction and TG2 SUMOylation. TG2 inhibition switches off inflammation in vitro as well as in vivo in a homozygous F508del-CFTR mouse model. Thus, TG2 may function as a link between oxidative stress and inflammation by driving the decision as to whether a protein should undergo SUMO-mediated regulation or degradation. Targeting TG2-SUMO interactions might represent a new option to control disease evolution in CF patients as well as in other chronic inflammatory diseases, neurodegenerative pathologies, and cancer.

[1]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[2]  J. Freyssinet,et al.  Mechanisms of the noxious inflammatory cycle in cystic fibrosis , 2009, Respiratory research.

[3]  N. Vij,et al.  CFTR Is a Negative Regulator of NFκB Mediated Innate Immune Response , 2009, PloS one.

[4]  Alan S. Verkman,et al.  Chloride channels as drug targets , 2009, Nature Reviews Drug Discovery.

[5]  Roberto Ravazzolo,et al.  TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity , 2008, Science.

[6]  D. Tempé,et al.  SUMO under stress. , 2008, Biochemical Society transactions.

[7]  G. Johnson,et al.  Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells , 2008, Journal of Biological Chemistry.

[8]  V. Villella,et al.  Tissue Transglutaminase Activation Modulates Inflammation in Cystic Fibrosis via PPARγ Down-Regulation1 , 2008, The Journal of Immunology.

[9]  J. Lieberman,et al.  Granzyme A Cleaves a Mitochondrial Complex I Protein to Initiate Caspase-Independent Cell Death , 2008, Cell.

[10]  Erik Meulmeester,et al.  Cell biology: SUMO , 2008, Nature.

[11]  M. Proesmans,et al.  What’s new in cystic fibrosis? From treating symptoms to correction of the basic defect , 2008, European Journal of Pediatrics.

[12]  M. Weller,et al.  Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis , 2008, Nature Medicine.

[13]  F. Melchior,et al.  Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.

[14]  Jiun L. Do,et al.  Effects of cystic fibrosis transmembrane conductance regulator and DeltaF508CFTR on inflammatory response, ER stress, and Ca2+ of airway epithelia. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[15]  F. Holsboer,et al.  RSUME, a Small RWD-Containing Protein, Enhances SUMO Conjugation and Stabilizes HIF-1α during Hypoxia , 2007, Cell.

[16]  J. Freyssinet,et al.  Exaggerated apoptosis and NF‐KB activation in pancreatic and tracheal cystic fibrosis cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  S. Gygi,et al.  Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells , 2007, Science.

[18]  V. Bours,et al.  Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. , 2007, Biochemical pharmacology.

[19]  R. Boucher,et al.  The epithelium as a target for therapy in cystic fibrosis. , 2007, Current opinion in pharmacology.

[20]  A. Verkman,et al.  CFTR inhibition mimics the cystic fibrosis inflammatory profile. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[21]  K. Jacobson,et al.  Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. , 2007, The Journal of clinical investigation.

[22]  Soo-Youl Kim,et al.  Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and Nuclear Factor-KB Inactivation , 2006 .

[23]  Huamin Wang,et al.  Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. , 2006, Cancer research.

[24]  P. Lebecque,et al.  Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice , 2006, Respiratory research.

[25]  S. Miyamoto,et al.  PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress , 2006, Nature Cell Biology.

[26]  M. Zou,et al.  Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. , 2006, The Journal of clinical investigation.

[27]  Amir Gamliel,et al.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ , 2005, Nature.

[28]  V. Raia,et al.  Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis , 2005, Thorax.

[29]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[30]  S. Randell,et al.  Cytokine secretion by cystic fibrosis airway epithelial cells. , 2004, American journal of respiratory and critical care medicine.

[31]  D. Dusser,et al.  Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-β kinase pathway , 2003, European Respiratory Journal.

[32]  Soo-Youl Kim,et al.  Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[34]  Dallas Jones,et al.  Emerging roles of PPARS in inflammation and immunity , 2002, Nature Reviews Immunology.

[35]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[36]  P. Rehbinder,et al.  Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units , 2002, Laboratory animals.

[37]  A. Kenworthy,et al.  Imaging protein-protein interactions using fluorescence resonance energy transfer microscopy. , 2001, Methods.

[38]  S. Jentsch,et al.  Ubiquitin and proteasomes: Sumo, ubiquitin's mysterious cousin , 2001, Nature Reviews Molecular Cell Biology.

[39]  J. Christman,et al.  Exaggerated Activation of Nuclear Factor- κ B and Altered I κ B- β Processing in Cystic Fibrosis Bronchial Epithelial Cells , 2000 .

[40]  H. Etlinger,et al.  the Journal of Immunology , 2006 .

[41]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[42]  L. Lorand,et al.  Neurodegenerative diseases and transglutaminase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Greenberg,et al.  Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid , 1996, Cell.

[44]  K. Gunderson,et al.  Failure of the Cystic Fibrosis Transmembrane Conductance Regulator to Conduct ATP , 1996, Science.

[45]  Satoshi Omura,et al.  Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.

[46]  T. McBride.  VEGETABLE MORPHOLOGY A CENTURY AGO. -- Goethe. , 1885, Science.

[47]  C. Rodolfo,et al.  Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. , 2008, Current pharmaceutical design.

[48]  T. Chin,et al.  Dual effect of thapsigargin on cell death in porcine aortic smooth muscle cells. , 2007, American journal of physiology. Cell physiology.

[49]  J. Chameau.  Corrections , 2006, Nature.

[50]  R. Kopito,et al.  Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. , 2003, Methods in molecular biology.

[51]  D. Geddes,et al.  Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. , 2001, The European respiratory journal.

[52]  R. Kopito,et al.  Biosynthesis and degradation of CFTR. , 1999, Physiological reviews.